Recent reports indicate a tumultuous time for Bayer, with stock prices experiencing both notable increases and significant falls. A key U.S legal win regarding the Roundup cancer claims has momentarily bolstered Bayer’s shares by 11%. Bayer's successful appeal over Roundup Cancer Suit led to another surge. However, a court-ordered payment of $2.25 billion in damages, and termination of asundexian trial pulled shares down by nearly 6% and to an 18-year low, respectively. The company faced backlash for its revealed turnaround plan, leading the chief to rule out capital increase. This combined with a dividend cut to manage their stifling debt led to a slip in Bayer's shares. The 2023 performance shows Bayer lost 28%, but strategic moves, including a collaboration with NextRNA for RNA-driven cancers and ORIC Pharmaceuticals helped cushion the slump. However, an acquisition from BridgeBio's Cardiovascular and risks due to debt usage indicates uncertainty going forward.
BAYER Stocks News Analytics from Fri, 27 Oct 2023 07:00:00 GMT to Sun, 01 Sep 2024 21:04:13 GMT - Rating -1 - Innovation -3 - Information 7 - Rumor -6